5 February 2024 - Valneva today announced it sold the priority review voucher it received from the US FDA for $103 million (€95 million).

The Company was awarded a tropical disease priority review voucher in November 2023 following US FDA approval of Ixchiq, Valneva’s single dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.

Read Valneva press release